Patent application number | Description | Published |
20080215086 | SINGLE DISC INTRALUMINAL FIXATION PATENT FORAMEN OVALE CLOSURE DEVICE - A device and method for deploying a mechanical closure device for closing a passageway in a body, for example a patent foramen ovale (PFO) in a heart. The single disc mechanical closure device is comprise of a distal and proximal anchor constrained by a closure line to facilitate mechanical closure by bringing the distal and proximal anchors into close proximity along the closure line. | 09-04-2008 |
20090171388 | VASCULAR CLOSURE DEVICE - A biocompatible material may be configured into any number of implantable medical devices including a vascular closure device. The vascular closure device includes a fibrous structure formed from at least one randomly oriented fiber, the randomly oriented fiber comprising at least one polymer, and at least one agent, in therapeutic dosage, incorporated into at least one of the fibrous structure and the at least one randomly oriented fiber. | 07-02-2009 |
20090318955 | VASCULAR CLOSURE DEVICE - The present invention provides a porous structure that works very effectively to seal a puncture site with optimum porosity, absorbent capacity and perfect anatomical fit. The plug density and other fiber properties/geometry (total denier; number of filaments; etc) have provided an efficient structure that allows instantaneous absorption of blood during deployment. The final size of the plug with absorbed fluids provides an anatomical fit and seals the puncture site within few minutes after deployment. | 12-24-2009 |
20110022080 | SINGLE DISC INTRALUMINAL FIXATION PATENT FORAMEN OVALE CLOSURE DEVICE - A device and method for deploying a mechanical closure device for closing a passageway in a body, for example a patent foramen ovale (PFO) in a heart. The single disc mechanical closure device is comprise of a distal and proximal anchor constrained by a closure line to facilitate mechanical closure by bringing the distal and proximal anchors into close proximity along the closure line. | 01-27-2011 |
20120197292 | PATENT FORAMEN OVALE CLOSURE METHOD - The present invention relates to devices for closing a passageway in a body, for example a patent foramen ovale (PFO) in a heart, and related methods of using such closure devices for closing the passageway. The method includes introducing a mechanical closure device into an atrium of the heart and transeptally deploying the closure device across the interatrial septum to provide proximation of the septum secundum and septum primum. | 08-02-2012 |
20130190811 | SINGLE DISC OCCLUSIONARY PATENT FORAMEN OVALE CLOSURE DEVICE - The present invention is a method and device for closing a passageway in a body, for example a patent foramen ovale (PFO) in a heart, and related methods of using such closure devices for closing the passageway. | 07-25-2013 |
20130296924 | PATENT FORAMEN OVALE CLOSURE DEVICE - A device and method for deploying a mechanical closure device for closing a passageway in a body, for example a patent foramen ovale (PFO) in a heart. The deployment device has a first tubular structure having proximal and distal ends. A second tubular structure is substantially coaxial to and slideably engaged within the first tubular structure. The second tubular structure has a first substantially linear shape when constrained within the first tubular structure, and a second curvilinear shape when telescopically extended from the distal end of the first tubular structure. A third tubular structure is substantially coaxial to and slideably engaged within the second tubular structure. The third tubular structure is configured to provide sufficient rigidity to push the mechanical closure device from the distal end of the second tubular structure, and provide sufficient flexibility to assume a curvilinear shape when deflected by the second tubular structure. | 11-07-2013 |
20140336700 | VASCULAR CLOSURE DEVICE - A biocompatible material may be configured into any number of implantable medical devices including a vascular closure device. The vascular closure device includes a fibrous structure formed from at least one randomly oriented fiber, the randomly oriented fiber comprising at least one polymer, and at least one agent, in therapeutic dosage, incorporated into at least one of the fibrous structure and the at least one randomly oriented fiber. | 11-13-2014 |
Patent application number | Description | Published |
20100098661 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS - The present invention relates to 4,5-ring annulated indole derivatives, compositions comprising at least one 4,5-ring annulated indole derivatives, and methods of using the 4,5-ring annulated indole derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. Wherein ring Z, of formula (I), is a cyclopentyl, cyclopentenyl, 5-membered heterocycloalkyl, 5-membered heterocycloalkenyl or 5-membered heteroaryl ring. | 04-22-2010 |
20100260711 | 3-AMINOSULFONYL SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to 3-Aminosulfonyl Substituted Indole Derivatives, compositions comprising at least one 3-Aminosulfonyl Substituted Indole Derivative, and methods of using the 3-Aminosulfonyl Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. | 10-14-2010 |
20100322901 | 5, 6-RING ANNULATED INDOLE DERIVATIVES AND USE THEREOF - The present invention relates to 5,6-ring annulated indole derivatives of the formula (I), compositions comprising at least one 5,6-ring annulated indole derivatives, and methods of using the 5,6-ring annulated indole derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. | 12-23-2010 |
20110033417 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS - The present invention relates to 2,3-Substituted Indole Derivatives, compositions comprising at least one 2,3-Substituted Indole Derivative, and methods of using the 2,3-Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. | 02-10-2011 |
20110104109 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS - The present invention relates to Tetracyclic Indole Derivatives, compositions comprising at least one Tetracyclic Indole Derivative, and methods of using the Tetracyclic Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. | 05-05-2011 |
20110104110 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to Substituted Indole Derivatives, compositions comprising at least one Substituted Indole Derivative, and methods of using these Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. | 05-05-2011 |
20110189127 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to Tricyclic Indole Derivatives, compositions comprising at least one Tricyclic Indole Derivatives, and methods of using the Tricyclic Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. | 08-04-2011 |
20120251491 | FUSED TRICYCLIC ARYL COMPOUNDS USEFUL FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to novel Fused Tricyclic Aryl Compounds, compositions comprising at least one Fused Tricyclic Aryl Compound, and methods of using the Fused Tricyclic Aryl Compounds for treating or preventing HCV infection in a patient. | 10-04-2012 |
20120258078 | ANTIVIRAL COMPOUNDS OF THREE LINKED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C - The present invention relates to novel Linked Tricyclic Aryl Compounds, compositions comprising at least one Linked Tricyclic Compound, and methods of using Linked Tricyclic Aryl Compounds for treating or preventing HCV infection in a patient. in one aspect, the present invention provides Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein: Non-limiting examples of the Compounds of Formula (II) include compound 56 | 10-11-2012 |
20120276047 | FUSED TRICYCLIC COMPOUNDS AND DERIVATIVES THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to novel fused tricyclic compounds, compositions comprising at least one fused tricyclic compound, and methods of using fused tricyclic compounds for treating or preventing a viral infection or a virus-related disorder in a patient. | 11-01-2012 |
20130164258 | Antiviral Compounds Composed of Three Aligned Aryl Moieties to Treat Diseases such as Hepatitis C - The present invention relates to novel Tricyclic Compounds, compositions comprising at least one Tricyclic Compound, and methods of using Tricyclic Compounds for treating or preventing a viral infection or a virus-related disorder in a patient. The present invention provides Tricyclic Compounds of Formula (I): Non-limiting examples of the Compounds of Formula (I) include compound 44 The Compounds of Formula (II) can be useful for inhibiting HCV viral replication or replicon activity, and for treating or pre-venting HCV infection in a patient. | 06-27-2013 |
20140221304 | 5'-SUBSTITUTED NUCLEOSIDE ANALOGS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to 5′-Substituted Nucleoside Analogs of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, Z, R | 08-07-2014 |
Patent application number | Description | Published |
20090092567 | OIL-CONTAINING COMPOSITIONS EXHIBITING REDUCED FEATHERING - The invention relates to compositions containing at least one oil, at least one silicone elastomer, at least one wax, at least one filler, and at least one coloring agent as well as to methods of making and using such compositions. | 04-09-2009 |
20090246159 | Composition and Process for Treating Keratinous Substrates With At Least Two Immiscible Cosmetic Compositions - A process for treating a keratinous substrate involving: (a) providing at least a first composition having a continuous phase whose major ingredient has a solubility parameter corresponding to δ; (b) providing at least a second composition having a continuous phase whose major ingredient has a solubility parameter corresponding to δ′; and (c) combining (a) and (b) prior to, or during, their application onto the keratinous substrate, and wherein the difference between δ and δ′ is greater than 12, and wherein the major ingredient is chosen from a hydrophilic polar material, an organic non-polar material and an inorganic non-polar material. | 10-01-2009 |
20110020255 | COMPOSITION CONTAINING A POLAR MODIFIED POLYMER - The invention relates to a physiologically acceptable composition, especially a cosmetic composition, comprising at least one polar modified polymer, as well as to methods of using such compositions. | 01-27-2011 |
20110129431 | COMPOSITION CONTAINING A POLYORGANOSILOXANE POLYMER, A THICKENING AGENT AND AT LEAST ONE VOLATILE ALCOHOL - The invention relates to a physiologically acceptable composition, especially a cosmetic composition, comprising (a) at least one polyorganosiloxane containing polymer comprising at least one moiety which comprises at least one polyorganosiloxane group consisting of 1 to about 1000 organosiloxane units in the chain of the moiety or in the form of graft, and at least two groups capable of establishing hydrogen interactions; (b) at least one volatile alcohol; and (c) at least one thickening agent, as well as to methods of using such compositions and kits containing such compositions. | 06-02-2011 |
20140170105 | COSMETIC COMPOSITIONS CONTAINING AN ALKOXYSILANE AND A SILSESQUIOXANE RESIN - The present invention relates to composition for styling hair comprising: (a) a first phase comprising: at least one alkoxysilane having at least one solubilizing functional group and at least one amino substituent; at least one water-soluble metal salt; at least one acidifying agent; and at least one cosmetically acceptable carrier comprising water; and (b) a second phase comprising: at least one silsesquioxane resin and at least one volatile solvent. The present invention also relates to methods of styling hair. | 06-19-2014 |
Patent application number | Description | Published |
20100227873 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF - The present invention provides compounds of Formula (I): | 09-09-2010 |
20110207734 | Azine Derivatives and Methods of Use Thereof - The present invention relates to Azine Derivatives, pharmaceutical compositions comprising the Azine Derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. | 08-25-2011 |
20110319434 | Bicyclic Heterocyclic Derivatives and Methods of Use Thereof - The present invention relates to novel Bicyclic Heterocyclic Derivatives, pharmaceutical compositions comprising the Bicyclic Heterocyclic Derivatives and the use of these compounds for treating or preventing treating allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a cognitive disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. | 12-29-2011 |
20120316154 | FUSED TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - The present invention relates to certain lactam ring-containing compounds of the Formula (I) and pharmaceutically acceptable salts thereof, wherein D, E, X | 12-13-2012 |
20130303517 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS - The invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), and their pharmaceutically acceptable salts, wherein J | 11-14-2013 |